Pegcetacoplan for 52 weeks results in sustained proteinuria reduction to remission (≤0.5 g/g) and normalization (≤0.2 g/g): Phase 3 VALIANT trial

Publication

ASN •
7 November, 2025 •
•

"Tiredness…That’s the main thing, this is why I work part time.": A thematic analysis of patient perspectives on care and unmet needs in C3G and primary IC-MPGN

Sanya Norouzi, Mingyi Huang, Carly Rich, Katie Gordon, Lucía Quintana-Gallardo, Elizabeth A Holdsworth, Fernando Caravaca-Fontán

Available materials

Poster

Publication

ASN •
7 November, 2025 •
•

Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons

Bradley P Dixon, Andrew S Bomback, Carly Rich, Mingyi Huang, Piotr Wojciechowski, Rose Chang, Fernando Caravaca-Fontán, Fadi Fakhouri

Available materials

Poster

Publication

ASN •
6 November, 2025 •
•

Management of Uncontrolled Gout Among Nephrology Professionals: Findings from a Medical Chart Audit

Hyon Choi, Nana Kragh, Amod Athavale, Bhavisha Desai, Amal Gulaid, Abiola Oladapo, Brittany Smith, Kenneth Saag

Available materials

Poster

Publication

ESPN •
17 October, 2025 •
•

Pegcetacoplan halts disease progression and reduces proteinuria in paediatric patients with C3G and primary IC-MPGN: Phase 3 VALIANT study results

Christoph Licht, Gema Ariceta, Yael Borovitz, Bradley P Dixon, Nayoa Fujita, Larry A Greenbaum, Antonio Mastrangelo, Nabil Melhem, Nicole CAJ Van de Kar, Marina Vivarelli, Dean Wallace, Virginia Taliadouros, Johan Szamosi, Katie Gordon, Zhongshen Wang, Carla M Nester

Available materials

Oral Presentation

Symposium

ESPN •
17 October, 2025 •
•

Decoding complement in C3G and primary IC-MPGN Exploring evolving paths in care

Sally Johnson, Francesca Diomedi Camassei, Dieter Haffner

Available materials

Slides

Publication

ESPN •
16 October, 2025 •
•

Pegcetacoplan for paediatric patients with C3 glomerulopathy or primary immune-complex mediated membranoproliferative glomerulonephritis: 52-week results from Phase 3, VALIANT Study

Nicole CAJ Van de Kar, Gema Ariceta, Yael Borovitz, Bradley P Dixon, Larry A Greenbaum, Christoph Licht, Antonio Mastrangelo, Nabil Melhem, Nayoa Fujita, Dean Wallace, Marina Vivarelli, Zhongshen Wang, Dima Decker, Johan Szamosi, Lucía Quintana-Gallardo, Carla M Nester

Available materials

Oral Presentation

Publication

IPTA •
18 September, 2025 •
•

Pegcetacoplan for post-transplant patients with complement 3 glomerulopathy or primary (idiopathic) immune-complex membranoproliferative glomerulonephritis: an analysis of the phase 2 NOBLE and phase 3 VALIANT trials

Andrew S Bomback, David Kavanagh, Daniel Zecher, Julien Zuber, Ondrej Vicklicky, Li Li, Luis López Lázaro, Fadi Fakhouri

Available materials

Poster

Pegcetacoplan for 52 weeks results in sustained proteinuria reduction to remission (≤0.5 g/g) and normalization (≤0.2 g/g): Phase 3 VALIANT trial

"Tiredness…That’s the main thing, this is why I work part time.": A thematic analysis of patient perspectives on care and unmet needs in C3G and primary IC-MPGN

Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons

Management of Uncontrolled Gout Among Nephrology Professionals: Findings from a Medical Chart Audit

Pegcetacoplan halts disease progression and reduces proteinuria in paediatric patients with C3G and primary ​ IC-MPGN: Phase 3 VALIANT study results

Decoding complement in C3G and primary IC-MPGN Exploring evolving paths in care

Pegcetacoplan for paediatric patients with​ C3 glomerulopathy or primary immune-complex mediated membranoproliferative glomerulonephritis: 52-week results from Phase 3, VALIANT Study

Pegcetacoplan for post-transplant patients with complement 3 glomerulopathy or primary (idiopathic) immune-complex membranoproliferative glomerulonephritis: an analysis of the phase 2 NOBLE and phase 3 VALIANT trials

Pegcetacoplan halts disease progression and reduces proteinuria in paediatric patients with C3G and primary IC-MPGN: Phase 3 VALIANT study results

Pegcetacoplan for paediatric patients with C3 glomerulopathy or primary immune-complex mediated membranoproliferative glomerulonephritis: 52-week results from Phase 3, VALIANT Study